A detailed history of Jpmorgan Chase & CO transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 91 shares of ELDN stock, worth $451. This represents 0.0% of its overall portfolio holdings.

Number of Shares
91
Previous 56 62.5%
Holding current value
$451
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$1.57 - $3.12 $54 - $109
35 Added 62.5%
91 $0
Q1 2024

May 10, 2024

SELL
$1.54 - $2.13 $1,438 - $1,989
-934 Reduced 94.34%
56 $0
Q4 2023

Feb 12, 2024

BUY
$1.12 - $1.86 $1,079 - $1,793
964 Added 3707.69%
990 $1,000
Q3 2023

Nov 14, 2023

BUY
$1.14 - $1.66 $29 - $43
26 New
26 $0
Q4 2021

Feb 10, 2022

SELL
$4.02 - $6.07 $80 - $121
-20 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$5.94 - $8.46 $118 - $169
20 New
20 $0

Others Institutions Holding ELDN

About Eledon Pharmaceuticals, Inc.


  • Ticker ELDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,756,800
  • Market Cap $68.2M
  • Description
  • Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...
More about ELDN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.